
    
      Patients will be treated once daily with Tarceva, twice daily with capecitabine for 14
      consecutive days, followed by 7 days off of capecitabine (a cycle is 21 days). At week 1 of
      each cycle a physical exam and blood work will be performed. Reassessment of tumor size will
      be conducted at 6 weeks (2 cycles), 12 weeks (4 cycles) and then every 9 weeks thereafter.
      Patients will remain on treatment until one of the following occur: disease progression,
      illness that prevents further treatment or unacceptable adverse events.
    
  